P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal Article
Cytokines Modulate Telomerase Activity in a Human Multiple Myeloma Cell Line
Masaharu Akiyama,Teru Hideshima,Toshiaki Hayashi,Yu-Tzu Tai,Constantine S. Mitsiades,Nicholas Mitsiades,Dharminder Chauhan,Paul G. Richardson,Nikhil C. Munshi,Kenneth C. Anderson +9 more
TL;DR: The results demonstrate that telomerase activity is related not only to transcriptional regulation of hTERT by NFkappaB but also to posttranscriptional regulation because of phosphorylation of h TERT by Akt kinase.
Journal ArticleDOI
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.
Teru Hideshima,Dharminder Chauhan,Toshiaki Hayashi,Masaharu Akiyama,Nicholas Mitsiades,Constantine S. Mitsiades,Klaus Podar,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson +9 more
TL;DR: Another novel mechanism is defined whereby PS-341 can overcome the growth and survival advantage in MM cells conferred by the BM milieu, and this effect on cytokine-induced gp130 signaling cascades may account, at least in part, for the remarkable preclinical sensitivity and clinical responses achieved in MM with PS- 341 treatment.
Journal ArticleDOI
Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
Suzanne Trudel,Nikoletta Lendvai,Nikoletta Lendvai,Rakesh Popat,Peter M. Voorhees,Brandi Reeves,Edward N. Libby,Paul G. Richardson,Larry D. Anderson,Heather J. Sutherland,Kwee Yong,Axel Hoos,Michele Gorczyca,Soumi Lahiri,Zangdong He,Daren Austin,Joanna Opalinska,Adam D. Cohen +17 more
TL;DR: At the identified recommended phase 2 dose, GSK2857916 was well tolerated and had good clinical activity in heavily pretreated patients, thereby indicating that this might be a promising candidate for the treatment of relapsed or refractory multiple myeloma.
Journal ArticleDOI
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
Jesús F. San-Miguel,Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,D. Irwin,Edward A. Stadtmauer,Thierry Facon,Jean Luc Harousseau,Dina Ben-Yehuda,Sagar Lonial,H. Goldschmidt,Donna E. Reece,J. Bladé,Mario Boccadoro,Jamie Cavenagh,Rachel Neuwirth,Anthony Boral,Dixie Lee Esseltine,KC Anderson +18 more
TL;DR: Results indicate that bortezomib is active and well tolerated in patients with relapsed MM with varying degrees of renal insufficiency, and is more effective than dexamethasone in overcoming the detrimental effect of renal impairment.
Journal ArticleDOI
Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40–Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications
Yu-Tzu Tai,Xian-Feng Li,Laurence Catley,Rory Coffey,Iris Breitkreutz,Jooeun Bae,Weihua Song,Klaus Podar,Teru Hideshima,Dharminder Chauhan,Robert L. Schlossman,Paul G. Richardson,Steven P. Treon,Iqbal S. Grewal,Nikhil C. Munshi,Kenneth C. Anderson +15 more
TL;DR: It is shown that the addition of lenalidomide to SGN-40 enhances cytotoxicity against MM cells, providing the framework for combined lenalidumide and S GN-40 in a new treatment paradigm to both target MM cells directly and induce immune effectors against MM.